Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ENXTAM:CSG
ENXTAM:CSGAerospace & Defense

Assessing CSG (ENXTAM:CSG) Valuation After Hunterbrook Short Reports And Sharp Share Volatility

CSG (ENXTAM:CSG) is back in focus after Hunterbrook Media published short seller reports questioning the company’s ammunition production, disclosures and governance. This prompted a firm rebuttal from CSG and sharp share price swings. See our latest analysis for CSG. Since Hunterbrook’s short seller reports, the stock’s recent momentum has clearly weakened, with a 7 day share price return of a 14.32% decline and a year to date share price return of a 51.97% decline, putting the €15.778 share...
NasdaqGS:TXG
NasdaqGS:TXGLife Sciences

10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative

10x Genomics (TXG) closed out FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM basic EPS loss of US$0.35. Over recent quarters, the company has seen revenue fluctuate between US$149.0 million and US$172.9 million, while quarterly basic EPS has moved between a loss of US$0.40 and a profit of US$0.28, highlighting an uneven path on the income line. For investors, the latest print keeps the focus on...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E

Arrowhead Pharmaceuticals (ARWR) opened 2026 with Q1 revenue of US$264.0 million and basic EPS of US$0.22, while trailing twelve month figures show revenue of US$1.1 billion and basic EPS of US$1.48 as the company stayed in profitable territory over the last year. Over recent quarters, revenue has moved from US$2.5 million in Q1 2025 to US$542.7 million in Q2 2025 and US$256.5 million in Q4 2025, with EPS shifting from a loss of US$1.39 per share in Q1 2025 to a profit of US$2.78 per share in...
OB:VAR
OB:VAROil and Gas

Vår Energi (OB:VAR) Valuation Check After Trudvang Carbon Capture Agreement

Why the Trudvang CCS agreement matters for Vår Energi stock The recent move in Vår Energi (OB:VAR) is closely linked to its new Memorandum of Understanding with Aker Solutions and KNCC on the Trudvang carbon capture and storage project on the Norwegian Continental Shelf. The agreement focuses on developing an integrated CO₂ transportation and storage chain using the Utsira Formation, backed by experience from Sleipner. It also signals a clearer role for Vår Energi in long term industrial...
NasdaqGS:INSG
NasdaqGS:INSGCommunications

Inseego (INSG) Q4 EPS Loss Tests Bullish Thesis Of Narrowing Losses

Inseego (INSG) has wrapped up FY 2025 with fourth quarter revenue of US$48.4 million and a basic EPS loss of US$0.03, alongside net income from continuing operations of a US$0.46 million loss. Over recent quarters, the company has seen revenue move from US$31.7 million in Q1 2025 to US$45.9 million in Q3 2025 and then US$48.4 million in Q4 2025. Quarterly EPS shifted between a loss of US$0.14 in Q1 2025, a profit of US$0.03 in Q3 2025, and back to a small loss in Q4 2025. This sets up a story...
NasdaqCM:TCX
NasdaqCM:TCXIT

Tucows (TCX) TTM Loss Of US$75.8 Million Reinforces Bearish Profitability Narrative

Tucows (TCX) has just wrapped up FY 2025 with Q4 revenue of about US$98.7 million and a basic EPS loss of US$1.98, alongside a Q4 net loss of US$22.0 million. Over the past six quarters, revenue has moved from US$92.3 million in Q3 2024 to US$98.7 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$3.86 in Q4 2024 to a loss of US$1.98 in the latest quarter. Trailing twelve month EPS currently sits at a loss of US$6.85 on revenue of US$390.3 million as margins remain under...
NYSE:NGVC
NYSE:NGVCConsumer Retailing

Natural Grocers Q1 2026 Margin And EPS Strength Reinforces Bullish Narratives Despite Slower Sales

Q1 2026 earnings snapshot Natural Grocers by Vitamin Cottage (NGVC) opened fiscal 2026 with Q1 revenue of US$335.6 million and basic EPS of US$0.49, setting the tone for its latest earnings update. The company reported revenue of US$330.2 million and EPS of US$0.43 in Q1 2025, compared with US$335.6 million and EPS of US$0.49 in Q1 2026. Trailing twelve month EPS stands at US$2.08 on revenue of about US$1.3 billion, with higher net profit margins and earnings growth framing the quarter as one...
TSX:EMA
TSX:EMAElectric Utilities

Emera (TSX:EMA) Margin Expansion Challenges Concerns Over Earnings Volatility

Emera (TSX:EMA) has just wrapped up FY 2025 with fourth quarter revenue of $2.0b, basic EPS of $0.23 and net income of $68 million, setting the tone for how investors will read the full year. Over the past few quarters, the company has seen revenue move from $1.8b in Q4 2024 to $2.7b in Q1 2025 and then between $2.0b and $2.1b through Q2 and Q3, while basic EPS ranged from $0.52 in Q4 2024 to $1.96 in Q1 2025 before landing at $0.76 in Q3 and $0.23 in Q4. This gives a clear sense of how...
NYSE:ED
NYSE:EDIntegrated Utilities

Consolidated Edison (ED) Earnings Growth And 12% Margin Reinforce Bullish Narratives

Consolidated Edison (ED) has wrapped up FY 2025 with fourth quarter revenue of US$3,994 million and basic EPS of US$0.82, alongside trailing twelve month revenue of US$16.9 billion and basic EPS of US$5.66, set against earnings growth of 11.2% over the past year and an average 10.5% per year over five years. Over recent periods, the company has seen quarterly revenue range from US$3,595 million to US$4,798 million while basic EPS moved between US$0.68 and US$2.26, giving investors a clearer...
TSXV:AFM
TSXV:AFMMetals and Mining

Assessing Alphamin Resources (TSXV:AFM) Valuation After Strong Q1 Results And Dividend Announcement

Alphamin Resources (TSXV:AFM) drew fresh attention after reporting first quarter 2026 results with sales of US$240.07 million and net income of US$64.42 million, alongside a declared semi-annual dividend of CA$0.13 per share. See our latest analysis for Alphamin Resources. The first quarter update has coincided with a strong 30 day share price return of 26.32% and a 1 year total shareholder return of 77.98%, suggesting momentum has been building around the stock. If solid earnings and a...
TSE:4543
TSE:4543Medical Equipment

Assessing Terumo (TSE:4543) Valuation After Recent Share Price Weakness

Recent share performance and business snapshot Terumo (TSE:4543) has drawn fresh attention after a one-month return of about an 11% decline and a past three-month return of about a 4% decline, prompting a closer look at fundamentals and valuation. The company reports annual revenue of ¥1,095,493m and net income of ¥127,903m, with year-on-year revenue growth of 6.37% and net income growth of 11.82%, and carries a value score of 4. See our latest analysis for Terumo. At a share price of...
NYSE:GRNT
NYSE:GRNTOil and Gas

Granite Ridge Resources (GRNT) One Off Loss Drives Q4 EPS Hit Challenges Bullish Narratives

Granite Ridge Resources (GRNT) has wrapped up FY 2025 with fourth quarter revenue of US$100.4 million and a basic EPS loss of US$0.19. Trailing twelve month revenue came in at US$427.9 million and basic EPS of US$0.19, as net profit margin moved to 5.8% from 5.3% a year earlier and earnings growth of 29.9% over the past year. Over recent periods the company has seen revenue move from US$359.0 million in the twelve months to Q4 2024 to US$427.9 million in the twelve months to Q4 2025. Over the...
NasdaqGS:SSP
NasdaqGS:SSPMedia

Scripps (SSP) Quarterly Net Loss Deepens Cautious Narratives Despite Stable Revenue Base

E.W. Scripps (SSP) just reported FY 2025 fourth quarter results with revenue of US$560.3 million and basic EPS of US$0.51 loss, set against a year earlier fourth quarter that showed revenue of US$728.4 million and basic EPS of US$0.93. Over recent periods the company has seen quarterly revenue move from US$646.3 million and EPS of US$0.37 in 2024 Q3 to US$560.3 million and EPS of US$0.51 loss in 2025 Q4. Trailing 12 month revenue sits at about US$2.2 billion with basic EPS of US$1.87 loss...
NasdaqGS:CRNC
NasdaqGS:CRNCSoftware

Cerence (CRNC) Revenue Surges To US$115.1 Million Testing Bullish Growth Narratives

Cerence (CRNC) opened Q1 2026 with total revenue of US$115.1 million, Basic EPS of a US$0.12 loss, and net income excluding extra items of a US$5.2 million loss, while the trailing 12 months show Basic EPS of roughly US$0.01 and net income excluding extra items of about US$0.3 million. Over recent quarters the company has seen revenue move from US$50.9 million in Q1 2025 to US$115.1 million in Q1 2026, alongside Basic EPS shifting from a US$0.57 loss to a US$0.12 loss and trailing 12 month...
TSE:6701
TSE:6701IT

Is There Now An Opportunity In NEC (TSE:6701) After Recent Share Price Weakness?

If you are wondering whether NEC at ¥4,200 is offering good value today, it helps to first line up the recent share performance with how the stock is currently priced. The stock has returned 4.1% over the last week and 0.3% over the last month, while year to date it is down 22.7% and the 1 year return sits at 12.6%, with a very large gain over 3 years and a 333.9% return over 5 years. These moves sit against a backdrop of ongoing coverage of NEC's role in software and IT solutions, along...
TSX:IGM
TSX:IGMCapital Markets

IGM Financial Q4 EPS Beat And 25.5% Margin Test Slower Growth Narratives

IGM Financial (TSX:IGM) has just wrapped up FY 2025 with Q4 revenue of $1.3b and basic EPS of $1.37, alongside net income of $322.4m, putting fresh numbers behind its recent earnings momentum. Over the past few quarters, revenue has moved from $1.2b in Q4 2024 to $1.1b in Q3 2025 and $1.0b in Q2 2025 before this latest $1.3b print, while basic EPS has ranged from $1.07 in Q4 2024 through $1.26 in Q3 2025 to $1.04 in Q2 2025, giving investors a clear view of how profit scales with the top...
NYSE:MCY
NYSE:MCYInsurance

A Look At Mercury General (MCY) Valuation After Its First Quarter Earnings Turnaround

Earnings turnaround puts Mercury General in focus Mercury General (MCY) is back on many investors’ radars after first quarter results showed revenue of US$1,539.81 million and net income of US$190.42 million, compared with a net loss a year earlier. See our latest analysis for Mercury General. The earnings rebound and steady dividend news have come alongside a 1 month share price return of 8.67% and a 1 year total shareholder return of 74.37%, which together point to solid momentum rather...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi‑Year Share Price Declines?

If you are wondering whether Sarepta Therapeutics at US$20.80 is starting to look like value or still carries too much risk, the recent share price and fundamentals give you a lot to weigh up. The stock has been under pressure, with returns of 0.4% decline over 7 days, 9.9% decline over 30 days, 2.4% decline year to date, 43.0% decline over 1 year and 82.7% decline over 3 years, while the 5 year return sits at 71.3% decline. Recent news around Sarepta Therapeutics has focused on its position...
NYSE:NHI
NYSE:NHIHealth Care REITs

National Health Investors Refocuses Portfolio On Private Pay Senior Housing

National Health Investors (NYSE:NHI) is selling its entire skilled nursing facility portfolio for $560 million. The company plans to redeploy proceeds into private-pay senior housing, including a seven-property portfolio in Colorado. This shift reduces exposure to skilled nursing and increases focus on private-pay assets that management views as offering more attractive risk adjusted returns. For investors watching NYSE:NHI, this move comes with the stock recently closing at $75.07 and...
NasdaqCM:ORGO
NasdaqCM:ORGOBiotechs

Organogenesis Holdings (ORGO) Q4 EPS Rebound Tests Bullish Earnings Ramp Narrative

Organogenesis Holdings (ORGO) closed FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, alongside net income of US$35.1 million that capped a profitable trailing twelve month period. The company has seen quarterly revenue move from US$126.7 million and EPS of US$0.05 in Q4 2024 to US$225.6 million and EPS of US$0.28 in Q4 2025. Trailing twelve month EPS shifted from roughly flat at US$0.01 in Q4 2024 to US$0.16 in Q4 2025, setting up a results season where the...
NasdaqGS:PACB
NasdaqGS:PACBLife Sciences

Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives

Pacific Biosciences of California (PACB) has just posted its FY 2025 numbers, with Q4 revenue at US$44.6 million and a basic EPS loss of US$0.13 set against trailing twelve month revenue of US$160.0 million and a TTM basic EPS loss of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue move between US$37.2 million and US$44.6 million, while basic EPS has ranged from a small profit of US$0.01 in FY 2024 Q4 to a loss of US$1.44 in FY 2025 Q1. This leaves...
NYSE:GENI
NYSE:GENIHospitality

Genius Sports (GENI) Q1 Loss Widening To US$55 Million Tests Bullish Profitability Narratives

Genius Sports (GENI) opened Q1 2026 with revenue of US$188 million, a basic EPS loss of US$0.21 per share, and net income loss of US$55 million, setting a cautious tone around near term profitability. The company has seen quarterly revenue move from US$144 million in Q1 2025 to US$188 million in Q1 2026, while basic EPS shifted from a loss of US$0.03 to a loss of US$0.21 over the same period. This puts the focus squarely on how efficiently that extra revenue is translating into results. For...